IP Library › Granted Patent US 12,491,231
Granted Patent B2
US 12,491,231 · App. 18/359,559 · Granted Dec 9, 2025

Methods of treating metabolic disorders with FGF21 variants

Inventors: Allison Goldfine (Wayland, MA); Byungdoo Alexander Yi (Cambridge, MA)
Assignee: Novartis AG
A61K38/1825A61K45/06A61P3/00A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,231
App. No.
18/359,559
Granted
Dec 9, 2025
Kind
B2
Abstract

Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.

Claims (16)

1 . A method of treating a metabolic disorder in a human subject in need thereof comprising:

subcutaneously administering a pharmaceutical composition comprising a human fibroblast growth factor 21 (FGF21) protein variant Fc fusion protein consisting of the amino acid sequence of SEQ ID NO: 11,

at a dose of 300 mg and a frequency of every 4 weeks,

wherein the metabolic disorder is selected from nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).

2 . The method of claim 1 , wherein the metabolic disorder is nonalcoholic steatohepatitis (NASH).

3 . The method of claim 1 , wherein the metabolic disorder is nonalcoholic fatty liver disease (NAFLD).

4 . The method of claim 1 , wherein the treating comprises or is characterized by reducing one or more of the following: liver fat content, elevated low-density lipoprotein cholesterol-C (LDL-C), total-C, and triglyceride in the human subject.

5 . The method of claim 1 , wherein the treating comprises or is characterized by increasing high-density lipoprotein cholesterol-C (HDL-C) levels in the human subject.

6 . The method of claim 1 , wherein the treating comprises or is characterized by reducing triglyceride levels in the human subject by at least about 40% or at least about 50%.

7 . The method of claim 1 , wherein the treating comprises or is characterized by reducing cardiovascular risk in the human subject.

8 . The method of claim 1 , wherein the human subject is 18 to 55 years of age.

9 . The method of claim 1 , wherein the human subject has a body mass index (BMI) within the range of 30 to 45 kg/m 2 , inclusive, with ethnic adjustment ≥27.5 for a subject of Asian descent or Asian ancestry.

10 . The method of claim 1 , wherein the human subject has triglyceride levels in the range of 150-500 mg/dL (1.69-5.65 mmol/L) when measured prior to administration of the human FGF21 protein variant Fc fusion protein.

11 . The method of claim 1 , wherein the pharmaceutical composition is provided in combination with one or more additional therapeutically active agents.

12 . The method of claim 11 , wherein the one or more additional therapeutically active agents is selected from compounds for treating obesity, diuretics, beta-blockers, alpha-blockers, angiotensin converting enzyme (ACE) inhibitors, Angiotensin II Receptor Blockers (ARBs), direct renin inhibitors, calcium channel blockers, central agonists, peripheral adrenergic blockers, vasodilators, insulin, alpha-glucosidase inhibitors, biguanides, dopamine agonist, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptides, meglitinides, sodium glucose transporter (SGLT) inhibitors, sulfonylureas, thiazolidinediones, amylinomimetics, statins, fibrates, aspirin, anticoagulants, or combination thereof.

13 . The method of claim 12 , wherein the sodium glucose transporter (SGLT) inhibitor is selected from dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, tofogliflozin, remogliflozin, luseogliflozin, ipragliflozin, atigliflozin, bexagliflozin, henagliflozin, licogliflozin, or a pharmaceutically acceptable salt thereof, or combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2024
From: GOLDFINE, ALLISON; YI, BYUNGDOO ALEXANDER
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH LNC.
Reel/Frame 066424/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2024
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 066424/0717 →
Continuity (3)
Continuation 16955023
Provisional Application 62609489 · Dec 22, 2017
Related Publication 20240115661A1 · Apr 11, 2024
References Cited (115)
US 6716626B1 · Itoh et al. · 2004 [cited by applicant]
US 7576190B2 · Glaesner et al. · 2009 [cited by applicant]
US 8188040B2 · Belouski et al. · 2012 [cited by applicant]
US 9006400B2 · Boettcher et al. · 2015 [cited by applicant]
US 9023791B2 · Boettcher et al. · 2015 [cited by applicant]
US 9266935B2 · Boettcher et al. · 2016 [cited by applicant]
US 10076554B2 · Boettcher · 2018 [cited by examiner]
US 10669323B2 · Boettcher · 2020 [cited by examiner]
US 11129874B2 · Boettcher et al. · 2021 [cited by applicant]
US 20070237768A1 · Glaesner et al. · 2007 [cited by applicant]
US 20100285131A1 · Belouski et al. · 2010 [cited by applicant]
US 20120052069A1 · Belouski et al. · 2012 [cited by applicant]
US 20120129766A1 · Boettcher et al. · 2012 [cited by applicant]
US 20130079500A1 · Boettcher et al. · 2013 [cited by applicant]
US 20130085098A1 · Dickinson et al. · 2013 [cited by applicant]
US 20130129724A1 · Boettcher et al. · 2013 [cited by applicant]
US 20130129725A1 · Fachin et al. · 2013 [cited by applicant]
US 20140142023A1 · Sommerfeld et al. · 2014 [cited by applicant]
US 20160051628A1 · Boettcher et al. · 2016 [cited by applicant]
US 20160193297A1 · Boeltcher · 2016 [cited by examiner]
US 20170065678A1 · Diener et al. · 2017 [cited by applicant]
US 20170166621A1 · Boettcher · 2017 [cited by examiner]
US 20200101137A1 · Diener et al. · 2020 [cited by applicant]
US 20210386824A1 · Boettcher et al. · 2021 [cited by applicant]
CN 106432510A · 2017 [cited by applicant]
EP 312592B1 · 1991 [cited by applicant]
EP 2392927A1 · 2011 [cited by applicant]
EP 3321276A2 · 2018 [cited by applicant]
EP 2760475B1 · 2018 [cited by applicant]
JP 2014534172A · 2014 [cited by applicant]
JP 2017519024A · 2017 [cited by applicant]
RU 2525393C2 · 2014 [cited by applicant]
RU 2593960C2 · 2016 [cited by applicant]
TW 201326213A1 · 2013 [cited by applicant]
WO WO2001018172A2 · 2001 [cited by applicant]
WO WO2003011213A2 · 2003 [cited by applicant]
WO WO2004003179A1 · 2004 [cited by applicant]
WO WO2004110472A2 · 2004 [cited by applicant]
WO WO2005000892A2 · 2005 [cited by applicant]
WO WO2005046682A1 · 2005 [cited by applicant]
WO WO2005061712A1 · 2005 [cited by applicant]
WO WO2005074916A1 · 2005 [cited by applicant]
WO WO2005113606A2 · 2005 [cited by applicant]
WO WO2006050247A2 · 2006 [cited by applicant]
WO WO2006078463A2 · 2006 [cited by applicant]
WO WO2008121563A2 · 2008 [cited by applicant]
WO WO2009020802A2 · 2009 [cited by applicant]
WO WO2009117622A2 · 2009 [cited by applicant]
WO WO2009149171A2 · 2009 [cited by applicant]
WO WO2010042747A2 · 2010 [cited by applicant]
WO WO2010084169A2 · 2010 [cited by applicant]
WO WO2010129503A1 · 2010 [cited by applicant]
WO WO2010129600A2 · 2010 [cited by applicant]
WO WO2011047267A1 · 2011 [cited by applicant]
WO WO2011071783A1 · 2011 [cited by applicant]
WO WO2011089170A2 · 2011 [cited by applicant]
WO WO2011089203A1 · 2011 [cited by applicant]
WO WO2011130417A2 · 2011 [cited by applicant]
WO WO2011154349A2 · 2011 [cited by applicant]
WO WO2012010553A1 · 2012 [cited by applicant]
WO WO2012040518A2 · 2012 [cited by applicant]
WO WO2012059873A2 · 2012 [cited by applicant]
WO WO2012066075A1 · 2012 [cited by applicant]
WO WO2012170438A2 · 2012 [cited by applicant]
WO WO2012177481A2 · 2012 [cited by applicant]
WO WO2013006486A2 · 2013 [cited by applicant]
WO WO2013010780A1 · 2013 [cited by applicant]
WO WO2013033452A2 · 2013 [cited by applicant]
WO WO2013049234A2 · 2013 [cited by applicant]
WO WO2013049247A1 · 2013 [cited by applicant]
WO WO2013052311A1 · 2013 [cited by applicant]
WO WO2013188181A1 · 2013 [cited by applicant]
WO WO2014031420A1 · 2014 [cited by applicant]
WO WO2014037373A1 · 2014 [cited by applicant]
WO WO2014085365A2 · 2014 [cited by applicant]
WO WO2014105939A1 · 2014 [cited by applicant]
WO WO2014149699A1 · 2014 [cited by applicant]
WO WO2015148708A1 · 2015 [cited by applicant]
WO WO2015183890A2 · 2015 [cited by applicant]
WO WO2015195509A2 · 2015 [cited by applicant]
WO WO2015200078A1 · 2015 [cited by applicant]
WO WO2016048999A2 · 2016 [cited by applicant]
WO WO2016065326A2 · 2016 [cited by examiner]
WO WO2017074117A1 · 2017 [cited by applicant]
Kharitonenkov et al., “FGF-21 as a novel metabolic regulator,” The Journal of Clinical Investigation 115(6):1627-1635 (2005). [cited by applicant]
Rader et al., “LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia,” J Clin Endocrinol Metab. 107(1):e57-e70 (2021) (14 pages). [cited by applicant]
Singhania et al., “Lipodystrophy in HIV patients: its challenges and management approaches,” HIV/AIDS—Research and Palliative Care 3:135-143 (2011). [cited by applicant]
Seckeler et al., “The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease,” Clin Epidemiol. 3:67-84 (Feb. 2011). [cited by applicant]
Armstrong, “Bristol Myers becomes latest victim of unforgiving NASH as midstage asset shelved,” Fierce Biotech, <https://www.fiercebiotech.com/biotech/bristol-myers-becomes-latest-victim-unforgiving-nash-as-mid-stage-as… [cited by applicant]
Charles et al., “Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study,” Obesity. 27(1):41-49 (Jan. 2019). [cited by applicant]
Clinical Trials: “Safety Study of LLF580 in Obese Volunteers,” <https://clinicaltrials.gov/ct2/show/NCT03466203>, dated Oct. 12, 2021, retrieved on Nov. 9, 2022 (7 pages). [cited by applicant]
Dong et al., “Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study,” Br J Clin Pharmacol. 80(5):1051-63 (Nov. 2015). [cited by applicant]
Gaich et al., “The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes,” Cell Metab. 18(3):333-40 (Sep. 3, 2013). [cited by applicant]
Kaufman et al., “AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients,” Cell Rep Med. 1(4):100057 (Jul. 21, 2020) (19 pages). [cited by applicant]
Kim et al., “Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese hypertriglyceridemic subjects an… [cited by applicant]
Sanyal et al., “Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial,” Lancet. 392(1… [cited by applicant]
Talukdar et al., “A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects,” Cell Metab. 23(3):427-40 (Mar. 8, 2016) (15 pages). [cited by applicant]
Verzijl et al., “Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis,” Expert Opin Investig Drugs. 29(2):125-133 (Feb. 2020) (10… [cited by applicant]
Kharitonenkov et al., “The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21,” Endocrinology. 148(2):774-81 (2007). [cited by applicant]
Office Action and Search Report for Russian Patent Application No. 2020123964/10(041376) mailed Aug. 3, 2022 (19 pages). [cited by applicant]
Harald Staiger et al: “Fibroblast Growth Factor 21-Metabolic Role in Mice and Men”, Endocrine Reviews, vol. 38, No. 5, Jul. 28, 2017 (Jul. 28, 2017), pp. 468-488, XP055575030, US, ISSN: 0163-769X, DOI: 10.1210/er.2017-0… [cited by applicant]
Murielle M. Veniant et al: “Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys”, Endocrinology, vol. 153, No. 9, Sep. 1, 2012 (Sep. 1, 2012), pp. 4192-4203, XP055268892, US, I… [cited by applicant]
Brown, T., et al., “Section 4.5 Concentrations of Solutions,” in: Chemistry The Central Science (New Jersey, Pearson Education, 2003) 9th Ed., pp. 134-136, ISBN: 0-13-066997-0. [cited by applicant]
Creighton, Thomas, “1.5 Determination of the Sizes of Proteins,” in: Proteins Structures and Molecular Properties (New York, W. H. Freeman and Company, 1993) 2nd Ed., pp. 23-24, ISBN: 0-7167-7030-X. [cited by applicant]
Harrison, et al., “Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (Harmony): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial,” (2023) Lancet G… [cited by applicant]
Harrison, et al., “Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial,” Nature Medicine, vol. 27, pp. 1262-1271, 2021. [cited by applicant]
Heckt, et at., “Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes,” PLOS One (2012) vol. 7, No. 11, e49345 (14 pages). [cited by applicant]
International Nonproprietary Name (INN), “Efimosfermin alpha,” WHO Drug Information, vol. 38, No. 3, (2024). [cited by applicant]
International Nonproprietary Name (INN), “Efruxifermin,” WHO Drug Information, vol. 35, No. 3, (2021). [cited by applicant]
International Nonproprietary Name (INN), “Pegozafermin,” WHO Drug Information, vol. 37, No. 1, (2023). [cited by applicant]
Loomba, et al., “Expert Panel Review to Compare FDA and EMA Guidelines on Drug Development and Endpoints in Nonalcoholic Steatohepatitis,” Gastroenterology (2022) vol. 162, No. 3, pp. 680-688. [cited by applicant]
Loomba, R, et al., “Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in Nash,” N Engl J Med. (2023) vol. 389, No. 11, pp. 998-1008. [cited by applicant]
Mathaes, et al., “Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries,” J. Pharm. Sci. (2016) vol. 105, No. 8: pp. 2255-2259. [cited by applicant]
Noureddin, et al., “Once-monthly Efimosfermin Alpha (BOS-580) in Metabolic Dysfunction-associated Steatohepatitis with FL/F3 Fibrosis: Results from a 24 Week, Randomized, Double-Blind, Placebo-controlled, Phase 2 Trial,… [cited by applicant]
Weng, et al., “Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing,” Sci. Rep. (2018) vol. 8: 4241 (15 pages). [cited by applicant]